Related Experiment Videos
Adjuvant chemotherapy for colorectal cancer
Anne Demols1, Jean-Luc Van Laethem
1Department of Gastroenterology, Erasme University Hospital, Route de Lennik, 808, 1070 Brussels, Belgium.
Current Gastroenterology Reports
|September 14, 2002
Summary
Colorectal cancer treatment involves surgery, with adjuvant chemotherapy standard for stage III colon cancer. Research explores new therapies like immunotherapy and cyclooxygenase-2 inhibitors for improved outcomes in early-stage disease.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Colorectal cancer is a leading cause of cancer mortality in Western nations.
- While surgery is curative, recurrence rates for stage III colon cancer are high (30-60%).
- Adjuvant chemotherapy (Mayo regimen) is standard for stage III colon cancer; its role in stage II is debated.
Purpose of the Study:
- To review current adjuvant treatment strategies for colon and rectal cancers.
- To highlight evolving therapeutic approaches in the adjuvant setting.
- To compare international standards for rectal cancer management.
Main Methods:
- Review of established treatment protocols for colon and rectal cancer.
- Discussion of ongoing clinical trials for novel adjuvant therapies.
- Comparison of European and US guidelines for rectal cancer management.
Main Results:
- Total mesorectum excision significantly reduces local recurrence in rectal cancer.
- Adjuvant chemotherapy is standard for stage III colon cancer.
- Neoadjuvant radiotherapy is preferred in Europe for resectable stage II/III rectal cancer, while adjuvant chemoradiotherapy is common in the US.
Conclusions:
- Surgical techniques like total mesorectum excision have improved rectal cancer outcomes.
- Adjuvant chemotherapy remains crucial for stage III colon cancer, with ongoing research into novel agents.
- International variations exist in neoadjuvant versus adjuvant therapy recommendations for rectal cancer.